Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamlanivimab for COVID-19 in high-risk patients (B-EPIC)
NCT04796402Phase 4Unknown
- Sponsor
- Fraser Health
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of bamlanivimab in coronavirus disease 2019 (COVID-19), sponsored by Fraser Health. Status: unknown.
02
Drugs
bamlanivimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04796402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796402.